Literature DB >> 32091337

The Role of Microglia in Neurodevelopmental Disorders and their Therapeutics.

Rachel Coomey1, Rianne Stowell2, Ania Majewska2, Daniela Tropea3,4.   

Abstract

The development of new therapeutics is critically dependent on an understanding of the molecular pathways, the disruption of which results in neurological symptoms. Genetic and biomarker studies have highlighted immune signalling as a pathway that is impaired in patients with neurodevelopmental disorders (NDDs), and several studies on animal models of aberrant neurodevelopment have implicated microglia, the brain's immune cells, in the pathology of these diseases. Despite the increasing awareness of the role of immune responses and inflammation in the pathophysiology of NDDs, the testing of new drugs rarely considers their effects in microglia. In this brief review, we present evidence of how the study of microglia can be critical for understanding the mechanisms of action of candidate drugs for NDDs and for increasing their therapeutic effect. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Genetic; Immune cells; Microglia; Neurodevelopmental disorders; Pathophysiology; Therapeutics.

Mesh：

Substances：

Year:  2020        PMID： 32091337      PMCID： PMC7323119          DOI： 10.2174/1568026620666200221172619

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN： 1568-0266            Impact factor:   3.295


  28 in total

1.  Host microbiota constantly control maturation and function of microglia in the CNS.

Authors:  Daniel Erny; Anna Lena Hrabě de Angelis; Diego Jaitin; Peter Wieghofer; Ori Staszewski; Eyal David; Hadas Keren-Shaul; Tanel Mahlakoiv; Kristin Jakobshagen; Thorsten Buch; Vera Schwierzeck; Olaf Utermöhlen; Eunyoung Chun; Wendy S Garrett; Kathy D McCoy; Andreas Diefenbach; Peter Staeheli; Bärbel Stecher; Ido Amit; Marco Prinz
Journal:  Nat Neurosci       Date:  2015-06-01       Impact factor: 24.884

2.  Wild-type microglia do not reverse pathology in mouse models of Rett syndrome.

Authors:  Jieqi Wang; Jan Eike Wegener; Teng-Wei Huang; Smitha Sripathy; Hector De Jesus-Cortes; Pin Xu; Stephanie Tran; Whitney Knobbe; Vid Leko; Jeremiah Britt; Ruth Starwalt; Latisha McDaniel; Chris S Ward; Diana Parra; Benjamin Newcomb; Uyen Lao; Cynthia Nourigat; David A Flowers; Sean Cullen; Nikolas L Jorstad; Yue Yang; Lena Glaskova; Sébastien Vingeau; Sebastian Vigneau; Julia Kozlitina; Michael J Yetman; Joanna L Jankowsky; Sybille D Reichardt; Holger M Reichardt; Jutta Gärtner; Marisa S Bartolomei; Min Fang; Keith Loeb; C Dirk Keene; Irwin Bernstein; Margaret Goodell; Daniel J Brat; Peter Huppke; Jeffrey L Neul; Antonio Bedalov; Andrew A Pieper
Journal:  Nature       Date:  2015-05-21       Impact factor: 49.962

3.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2.

Authors:  R E Amir; I B Van den Veyver; M Wan; C Q Tran; U Francke; H Y Zoghbi
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.

Authors:  Antonio Y Hardan; Lawrence K Fung; Robin A Libove; Tetyana V Obukhanych; Surekha Nair; Leonore A Herzenberg; Thomas W Frazier; Rabindra Tirouvanziam
Journal:  Biol Psychiatry       Date:  2012-02-18       Impact factor: 13.382

Review 5.  Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review.

Authors:  John Slattery; Nihit Kumar; Leanna Delhey; Michael Berk; Olivia Dean; Charles Spielholz; Richard Frye
Journal:  Neurosci Biobehav Rev       Date:  2015-05-06       Impact factor: 8.989

6.  Microglial activation in young adults with autism spectrum disorder.

Authors:  Katsuaki Suzuki; Genichi Sugihara; Yasuomi Ouchi; Kazuhiko Nakamura; Masami Futatsubashi; Kiyokazu Takebayashi; Yujiro Yoshihara; Kei Omata; Kaori Matsumoto; Kenji J Tsuchiya; Yasuhide Iwata; Masatsugu Tsujii; Toshirou Sugiyama; Norio Mori
Journal:  JAMA Psychiatry       Date:  2013-01       Impact factor: 21.596

7.  Antineuroinflammatory therapy: potential treatment for autism spectrum disorder by inhibiting glial activation and restoring synaptic function.

Authors:  Yong-Jiang Li; Xiaojie Zhang; Ya-Min Li
Journal:  CNS Spectr       Date:  2019-10-29       Impact factor: 3.790

8.  Induction of hippocampal long-term potentiation increases the morphological dynamics of microglial processes and prolongs their contacts with dendritic spines.

Authors:  Thomas Pfeiffer; Elena Avignone; U Valentin Nägerl
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

9.  Transcriptome analysis of microglia in a mouse model of Rett syndrome: differential expression of genes associated with microglia/macrophage activation and cellular stress.

Authors:  Dejian Zhao; Ryan Mokhtari; Erika Pedrosa; Rayna Birnbaum; Deyou Zheng; Herbert M Lachman
Journal:  Mol Autism       Date:  2017-03-29       Impact factor: 7.509

10.  Microglia contribute to circuit defects in Mecp2 null mice independent of microglia-specific loss of Mecp2 expression.

Authors:  Dorothy P Schafer; Christopher T Heller; Georgia Gunner; Molly Heller; Christopher Gordon; Timothy Hammond; Yochai Wolf; Steffen Jung; Beth Stevens
Journal:  Elife       Date:  2016-07-26       Impact factor: 8.140
View more
  3 in total

Review 1.  Epigenetics and Neuroinflammation Associated With Neurodevelopmental Disorders: A Microglial Perspective.

Authors:  Munekazu Komada; Yuhei Nishimura
Journal:  Front Cell Dev Biol       Date:  2022-05-12

2.  Luteolin Treatment Ameliorates Brain Development and Behavioral Performance in a Mouse Model of CDKL5 Deficiency Disorder.

Authors:  Marianna Tassinari; Nicola Mottolese; Giuseppe Galvani; Domenico Ferrara; Laura Gennaccaro; Manuela Loi; Giorgio Medici; Giulia Candini; Roberto Rimondini; Elisabetta Ciani; Stefania Trazzi
Journal:  Int J Mol Sci       Date:  2022-08-05       Impact factor: 6.208

Review 3.  Histamine, Neuroinflammation and Neurodevelopment: A Review.

Authors:  Elliott Carthy; Tommas Ellender
Journal:  Front Neurosci       Date:  2021-07-14       Impact factor: 4.677
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.